Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+
Hematology in Clinical Practice · 2021
DOI: 10.5603/hcp.2021.0004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2021. Verfasst von Oliwia Bachanek-Mitura und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bachanek-Mitura, O., Szudy-Szczyrek, A., & Hus, M. (2021). Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2021.0004
Vancouver
Bachanek-Mitura O, Szudy-Szczyrek A, Hus M. Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+. Hematology in Clinical Practice. 2021. doi:10.5603/hcp.2021.0004
BibTeX
@article{BachanekMitura2021,
author = {Bachanek-Mitura, Oliwia and Szudy-Szczyrek, Aneta and Hus, Marek},
title = {Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+},
journal = {Hematology in Clinical Practice},
year = {2021},
doi = {10.5603/hcp.2021.0004}
}
EUVIMED